by Korea JoongAng Daily

“Pharmaceutical company Chong Kun Dang signed a $1.3-billion technology transfer agreement with Novartis for its rare genetic disease treatment candidate.
 
The technology transfer deal, signed on Monday, is the largest ever for the Korean pharmaceutical company.
 
Chong Kun Dang’s CKD-510, a histone deacetylase 6 (HDAC6) inhibitor, is a drug candidate for Charcot-Marie-Tooth disease, which is a rare, hereditary genetic condition that causes muscle weakness. HDAC6 is an enzyme involved with inflammatory responses, and inhibiting it can dampen those responses…”

Continue reading at the original source, linked here.